Intellectual PROPERTY rights

Isofol has an active strategy to protect the company’s intellectual property rights and to ensure that these cover the markets that are important to the company. The patent portfolio covers both the formulation technology, dosage regime and use.

To protecting company and trade secrets is an important strategic area for the company in order to ensure the company’s commercial freedom of action and and achieve the company’s vision. Isofol works continuously and proactively to protect the intellectual property rights of arfolitixorin. The patent portfolio consists of several types of patents; substance, formulation and how they should be used in treatment.

The intellectual property protection for arfolitixorin currently comprises a combination of substance patents (owned by Merck) and clinical use patents (owned by Isofol), which together provide robust protection and market exclusivity in key global markets. In parallel with arfolitixorin’s clinical development, efforts continue to further expand the scope and extent of intellectual property protection. The substance arfolitixorin is patent-protected until 2037 in the U.S. and until 2034 in other markets. Additionally, the European Patent Office has issued a positive preliminary opinion regarding a new international substance patent that could extend protection until 2043, pending approval by national patent authorities. Furthermore, the new dosage regimen currently under testing could lead to additional patents providing exclusivity until 2045 if granted, and potentially beyond if patent term extensions are approved.

Working with leading patent experts, the company continuously evaluates opportunities to file new patents based on potential discoveries emerging from ongoing development work, which could further extend exclusivity protection and potentially increase the value of the company’s pharmaceutical projects even more.

Last updated 04-11-2025